Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

969030

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent steps the Government has taken to ensure that (a) negotiations between Vertex Pharmaceuticals and NHS England on access to Orkambi for people with cystic fibrosis proceed without further delay and (b) an agreement is reached between the two parties.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	171383
answer	answer is ministerial correction date of answer 14/09/2018 answer text <p>It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. While Ministers are keeping a very close eye on negotiations, it is the responsibility of NHS England as the commissioner and the National Institute for Health and Care Excellence (NICE) as the independent body that is responsible for making recommendations on whether drugs and other treatments represent a clinically and cost-effective use of NHS resources, to work with Vertex to agree a deal to secure the best outcome for patients and a price for Orkambi that is fair and responsible.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS. This would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are pleased to hear that it has responded positively to NHS England’s and NICE’s latest offer to meet. The Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy), the Secretary of State for Health (Rt. hon. Matt Hancock MP) and I have and continue to urge Vertex to reconsider this fair offer.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171384 question first answered 14/09/2018 13:32:27 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

969031

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the oral contribution of the Parliamentary Under-Secretary of State for Health and Social Care of 17 July 2018, Official Report, column 384, what progress the Government has made on access to Orkambi in England since Vertex Pharmaceuticals was called on to accept NHS England’s proposal to make that drug available to people with cystic fibrosis.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	171384
answer	answer is ministerial correction date of answer 14/09/2018 answer text <p>It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. While Ministers are keeping a very close eye on negotiations, it is the responsibility of NHS England as the commissioner and the National Institute for Health and Care Excellence (NICE) as the independent body that is responsible for making recommendations on whether drugs and other treatments represent a clinically and cost-effective use of NHS resources, to work with Vertex to agree a deal to secure the best outcome for patients and a price for Orkambi that is fair and responsible.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS. This would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are pleased to hear that it has responded positively to NHS England’s and NICE’s latest offer to meet. The Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy), the Secretary of State for Health (Rt. hon. Matt Hancock MP) and I have and continue to urge Vertex to reconsider this fair offer.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171383 question first answered 14/09/2018 13:32:27 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

942538

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care what plans he has to ensure his Department continues to engage and meet with NHS England and Vertex to discuss access to Orkambi.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	164468
answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 10:09:26 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

942539

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether ensuring access to Orkambi for people with cystic fibrosis is a priority for his Department.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	164469
answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>It is a key commitment of this Government to ensure that people with comparatively rarer conditions, like cystic fibrosis, get the same quality, safety and efficacy in medicines as those who have more common conditions.</p><p> </p><p>However, it is also necessary that Vertex prices Orkambi fairly and responsibly. That is why we must go through the right process with Vertex and NHS England, not the Government, working together to secure the best outcome for patients. NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 10:10:54 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

942540

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether a date has been set for the next meeting between NHS England and Vertex to discuss access to the drug Orkambi.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	164470
answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>We are informed by NHS England that at the last meeting on 4 July, it was agreed that both parties would take time to reflect before a further meeting was arranged. NHS England has subsequently made a substantially increased proposal to Vertex and has offered to meet to discuss and clarify any aspects as required by the company.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 09:48:08 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

942541

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his Department's policy is on Vertex (a) waiving its confidentiality clause on the negotiations around NHS access to the drug Orkambi and (b) disclosing details of its offer to NHS England.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	164471
answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>It is not in the Department’s gift to impose any requirement upon Vertex to waive its confidentiality clause or to disclose details of any offer in the negotiations around National Health Service access to the drug Orkambi. However, Ministers at the department have publicly urged Vertex to consider the offer made by NHS England and to waive confidentiality so that we can all see, in the interests of transparency, the kind of prices it is seeking to charge the NHS.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 09:43:39 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

903758

registered interest
date	14/05/2018
answering body	Department for Education
answering dept id	60
answering dept short name	Education
answering dept sort name	Education
hansard heading	Teachers: Bureaucracy
house id	1
legislature	25259 pref label House of Commons
question text	What steps he has taken to reduce teacher workload.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	905269
answer	answer is ministerial correction date of answer 14/05/2018 answer text <p>The Workload Challenge identified three key areas driving excess workload: dialogic marking policies; excessive data collection; and lesson planning approaches.</p><p>We have taken steps to address each of these, as well as making a commitment for stability in assessment, qualifications and curriculum reform. This gives our education reforms - that are rasing standards in our schools - time to bed in.</p> answering member constituency Bognor Regis and Littlehampton answering member printed Nick Gibb question first answered 14/05/2018 17:00:17 answering member 111 label Biography information for Nick Gibb
tabling member	4450 label Biography information for Luke Hall

871712

registered interest
date	26/03/2018
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Universal Credit
house id	1
legislature	25259 pref label House of Commons
question text	What steps she is taking to ensure that universal credit supports people in progressing at work and increasing their earnings.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	904567
answer	answer is ministerial correction date of answer 26/03/2018 answer text <p>Universal Credit provides us with the opportunity to support people to progress in work and we are currently developing the evidence base on how best to do this.</p><p> </p><p>Building on our existing suite of trials, which includes a large scale Randomised Control Trial on in-work progression, we have committed an additional £8m to testing different approaches to supporting people to progress.</p> answering member constituency Reading West answering member printed Alok Sharma question first answered 26/03/2018 16:15:15 answering member 4014 label Biography information for Sir Alok Sharma
tabling member	4450 label Biography information for Luke Hall

867295

registered interest
date	20/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Children and Young People
house id	1
legislature	25259 pref label House of Commons
question text	What steps he is taking to improve the provision of mental health services for children and young people.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	904476
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>We are making an additional £1.4 billion available until 2019/20 in order to transform services and ensure access to specialist mental health services for 70,000 additional children and young people each year by 2020/21.</p><p> </p><p>Our recent Green Paper published jointly with the Department for Education, will revolutionise services in schools, bolster links between schools and commits us to pilot a four week waiting time for National Health Service specialist services.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 20/03/2018 14:43:54 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4450 label Biography information for Luke Hall

862108

registered interest
date	14/03/2018
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Income Tax: Thornbury and Yate
house id	1
legislature	25259 pref label House of Commons
question text	To ask Mr Chancellor of the Exchequer, how many people in the Thornbury and Yate constituency his Department estimates will benefit from the rise in tax free personal allowance during the 2018-2019 financial year.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	132527
answer	answer is ministerial correction date of answer 19/03/2018 answer text <p>Since the start of the 2015 Parliament, increases to the personal allowance (up to £11,850 in 2018-19) are expected to cut income tax for 2.8 million individuals in the South West, which includes Gloucestershire and the Parliamentary Constituency of Thornbury and Yate.</p><p> </p><p>These estimates are based on the 2014-15 Survey of Personal Incomes, projected using economic assumptions consistent with the Office for Budget Responsibility’s November 2017 Economic and Fiscal Outlook.</p><p> </p><p>HM Treasury does not publish this information at constituency level or unitary authority level.</p> answering member constituency Central Devon answering member printed Mel Stride grouped question UIN 132528 132529 question first answered 19/03/2018 14:07:28 answering member 3935 label Biography information for Mel Stride
tabling member	4450 label Biography information for Luke Hall